Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 12/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | FASN | P49327 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167838 | 0.81 | PRMT3 (0.44) | PRMT3HPGDMMP13KDM2B | |
| SCHEMBL10135799 | 0.78 | PRMT3 (0.49) | PRMT3 | |
| SCHEMBL566185 | 0.76 | ATM (0.53) | PRMT3 | |
| Hydrochloric Acid SCHEMBL567277 | 0.75 | ATM (0.52) | PRMT3 | |
| SCHEMBL10135802 | 0.70 | PRMT3 (0.43) | PRMT3PIM1KDM2B | |
| SCHEMBL568035 | 0.68 | MMP1 (0.48) | PRMT3MMP13 | |
| SCHEMBL568036 | 0.68 | MMP1 (0.48) | PRMT3MMP13 | |
| Hydrochloric Acid SCHEMBL566459 | 0.68 | MMP1 (0.49) | PRMT3MMP13 | |
| Hydrochloric Acid SCHEMBL566458 | 0.68 | MMP1 (0.49) | PRMT3MMP13 | |
| SCHEMBL10135806 | 0.68 | PRMT3 (0.43) | PRMT3HPGDPIM1KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | PRMT3 237/4885HPGD 2697/4885FASN 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.